CEPI

Over 8 million people. That is the number of people who might be alive today if the international community had accomplished the 100 Days Mission to develop safe and effective new vaccines against SARS-CoV-2 in three months. 👉 cepi.net/100-days-save-… @imperialcollege…

📣CEPI and @ICMRDELHI have signed a new MoU to strengthen collaboration on developing accessible, affordable vaccines against emerging and re-emerging infectious diseases.

In our latest Innovations for Impact story, discover the ways in which cutting-edge #AI techniques are helping CEPI-backed scientists to reimagine how, and how quickly, the world could develop new vaccines against a potential #H5N1 pandemic threat. bit.ly/4kU9s4x

We're joining forces with @PATHtweets to create playbooks mapping out the immune markers that signal protection against Lassa fever, Mpox, Marburg and Ebola viruses. The US$8m project will advance R&D efforts against these deadly pathogens cepi.net/rd-experts-cre…

In collaboration with @CepiVaccines, we’re excited to begin the third quarterly follow-up and blood sampling for participants enrolled in the #ENABLE Project at FMC Owo. Together, we’re generating vital scientific data to guide vaccine development and strengthen the global…

Compared to traditional purification methods, @popbiotech's SNAP™ nanoparticle technology could rapidly purify antigens added to protein-based infectious disease vaccines💉 CEPI is awarding up to $1.5 million to advance research into the platform: cepi.net/new-protein-va…

Following the successful completion of the 2nd quarterly follow-up and blood sampling, we are pleased to commence the 3rd round of follow-up and blood sampling for enrolled participants in the ENABLE Project at Irrua Specialist Teaching Hospital (ISTH). This activity is…

📣Scientists are exploring how early vaccine studies can safely support faster vaccine approvals through a new project called FEEVA. FEEVA is funded by CEPI and @wellcometrust and led by @UNSW Kirby Institute and @MonashUni Australian Living Evidence Collaboration:…

Listen for this week's episode of A Common Health, from @CSIS, in which I had the great pleasure to host the inimitable @DrRHatchett CEO of @CEPIvaccines. As always, Richard delivers not only wisdom, but also desperately needed optimism. csis.org/podcasts/commo…

Nipah virus kills up to 75% of those infected, yet there are no approved vaccines to defend against it. CEPI is a lead funder of Nipah vaccines, with two candidates on the verge of Phase 2 trials. Learn more about global efforts to combat Nipah virus ⬇️ bit.ly/4f0xauw

📣DEADLINE EXTENDED! Submit a one-page Research Proposal summary by the new August 7 deadline. If you've already submitted, you can reopen and update your proposal. Don't miss out! bit.ly/3Ufw3gV

“If we are serious about responding effectively to future pandemic threats—if we even want to dream about preventing future pandemics—we must master the execution and mechanics of response.” @CEPIvaccines CEO @DrRHatchett shares how speedy response is the key to saving lives…

Remember 2009's H1N1 pandemic? Rich countries bought up almost all vaccines while the rest of the world waited. @CEPIvaccines Deputy CEO @AureliaFNguyen shares how the approach to the COVID-19 response was designed with equity in mind: bit.ly/404IDmK

"If we want to dream about preventing future pandemics—we must master the execution and mechanics of response" - great insights from @CEPIvaccines' @DrRHatchett on why speed, scale and access are critical for preventing & neutralising pandemic threats:bit.ly/4kiVZCR